Steroid treatment for severe childhood IgA nephropathy: a randomized, controlled trial.

Norishige Yoshikawa, Masataka Honda, Kazumoto Iijima, Midori Awazu, Shinzaburou Hattori, Koichi Nakanishi, Hiroshi Ito

Research output: Contribution to journalArticle

75 Citations (Scopus)

Abstract

A previous trial showed that treatment of children with severe IgA nephropathy (IgAN) using prednisolone, azathioprine, heparin-warfarin, and dipyridamole for 2 yr early in the course of disease reduced the severity of immunologic renal injury and prevented any increase in the percentage of sclerosed glomeruli. This study compared the effects of prednisolone, azathioprine, warfarin, and dipyridamole (combination) with those of prednisolone alone in 80 children with newly diagnosed IgAN that showed diffuse mesangial proliferation. Patients were randomly assigned to receive either the combination or prednisolone alone for 2 yr. The primary end point was the disappearance of proteinuria, defined as urinary protein excretion <0.1 g/m2 per d, and the secondary end points were urinary protein excretion at the end of treatment, the change in the percentage of sclerosed glomeruli during the trial, and adverse effects. The two study groups were similar in terms of baseline characteristics. Thirty-nine of the 40 patients who received the combination and 39 of the 40 who received prednisolone completed the trial. Thirty-six (92.3%) of the 39 patients who received the combination and 29 (74.4%) of the 39 who received prednisolone reached the primary end point by the 2-yr follow-up point (P = 0.007 log-rank). The percentage of sclerosed glomeruli was unchanged in the patients who received the combination but increased from 3.1 +/- 4.8 to 14.6 +/- 15.2% in the prednisolone group (P = 0.0003). The frequency of adverse effects was similar in the two groups. It is concluded that combination treatment may be better for severe IgAN than treatment with prednisolone alone.

Original languageEnglish
Pages (from-to)511-517
Number of pages7
JournalClinical journal of the American Society of Nephrology : CJASN
Volume1
Issue number3
DOIs
Publication statusPublished - 2006 May
Externally publishedYes

Fingerprint

Prednisolone
Immunoglobulin A
Randomized Controlled Trials
Steroids
Dipyridamole
Azathioprine
Warfarin
Therapeutics
Proteinuria
Heparin
Proteins
Kidney
Wounds and Injuries

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Steroid treatment for severe childhood IgA nephropathy : a randomized, controlled trial. / Yoshikawa, Norishige; Honda, Masataka; Iijima, Kazumoto; Awazu, Midori; Hattori, Shinzaburou; Nakanishi, Koichi; Ito, Hiroshi.

In: Clinical journal of the American Society of Nephrology : CJASN, Vol. 1, No. 3, 05.2006, p. 511-517.

Research output: Contribution to journalArticle

Yoshikawa, Norishige ; Honda, Masataka ; Iijima, Kazumoto ; Awazu, Midori ; Hattori, Shinzaburou ; Nakanishi, Koichi ; Ito, Hiroshi. / Steroid treatment for severe childhood IgA nephropathy : a randomized, controlled trial. In: Clinical journal of the American Society of Nephrology : CJASN. 2006 ; Vol. 1, No. 3. pp. 511-517.
@article{76419c86b03b487eab950d6efb27095b,
title = "Steroid treatment for severe childhood IgA nephropathy: a randomized, controlled trial.",
abstract = "A previous trial showed that treatment of children with severe IgA nephropathy (IgAN) using prednisolone, azathioprine, heparin-warfarin, and dipyridamole for 2 yr early in the course of disease reduced the severity of immunologic renal injury and prevented any increase in the percentage of sclerosed glomeruli. This study compared the effects of prednisolone, azathioprine, warfarin, and dipyridamole (combination) with those of prednisolone alone in 80 children with newly diagnosed IgAN that showed diffuse mesangial proliferation. Patients were randomly assigned to receive either the combination or prednisolone alone for 2 yr. The primary end point was the disappearance of proteinuria, defined as urinary protein excretion <0.1 g/m2 per d, and the secondary end points were urinary protein excretion at the end of treatment, the change in the percentage of sclerosed glomeruli during the trial, and adverse effects. The two study groups were similar in terms of baseline characteristics. Thirty-nine of the 40 patients who received the combination and 39 of the 40 who received prednisolone completed the trial. Thirty-six (92.3{\%}) of the 39 patients who received the combination and 29 (74.4{\%}) of the 39 who received prednisolone reached the primary end point by the 2-yr follow-up point (P = 0.007 log-rank). The percentage of sclerosed glomeruli was unchanged in the patients who received the combination but increased from 3.1 +/- 4.8 to 14.6 +/- 15.2{\%} in the prednisolone group (P = 0.0003). The frequency of adverse effects was similar in the two groups. It is concluded that combination treatment may be better for severe IgAN than treatment with prednisolone alone.",
author = "Norishige Yoshikawa and Masataka Honda and Kazumoto Iijima and Midori Awazu and Shinzaburou Hattori and Koichi Nakanishi and Hiroshi Ito",
year = "2006",
month = "5",
doi = "10.2215/CJN.01120905",
language = "English",
volume = "1",
pages = "511--517",
journal = "Clinical journal of the American Society of Nephrology : CJASN",
issn = "1555-9041",
publisher = "American Society of Nephrology",
number = "3",

}

TY - JOUR

T1 - Steroid treatment for severe childhood IgA nephropathy

T2 - a randomized, controlled trial.

AU - Yoshikawa, Norishige

AU - Honda, Masataka

AU - Iijima, Kazumoto

AU - Awazu, Midori

AU - Hattori, Shinzaburou

AU - Nakanishi, Koichi

AU - Ito, Hiroshi

PY - 2006/5

Y1 - 2006/5

N2 - A previous trial showed that treatment of children with severe IgA nephropathy (IgAN) using prednisolone, azathioprine, heparin-warfarin, and dipyridamole for 2 yr early in the course of disease reduced the severity of immunologic renal injury and prevented any increase in the percentage of sclerosed glomeruli. This study compared the effects of prednisolone, azathioprine, warfarin, and dipyridamole (combination) with those of prednisolone alone in 80 children with newly diagnosed IgAN that showed diffuse mesangial proliferation. Patients were randomly assigned to receive either the combination or prednisolone alone for 2 yr. The primary end point was the disappearance of proteinuria, defined as urinary protein excretion <0.1 g/m2 per d, and the secondary end points were urinary protein excretion at the end of treatment, the change in the percentage of sclerosed glomeruli during the trial, and adverse effects. The two study groups were similar in terms of baseline characteristics. Thirty-nine of the 40 patients who received the combination and 39 of the 40 who received prednisolone completed the trial. Thirty-six (92.3%) of the 39 patients who received the combination and 29 (74.4%) of the 39 who received prednisolone reached the primary end point by the 2-yr follow-up point (P = 0.007 log-rank). The percentage of sclerosed glomeruli was unchanged in the patients who received the combination but increased from 3.1 +/- 4.8 to 14.6 +/- 15.2% in the prednisolone group (P = 0.0003). The frequency of adverse effects was similar in the two groups. It is concluded that combination treatment may be better for severe IgAN than treatment with prednisolone alone.

AB - A previous trial showed that treatment of children with severe IgA nephropathy (IgAN) using prednisolone, azathioprine, heparin-warfarin, and dipyridamole for 2 yr early in the course of disease reduced the severity of immunologic renal injury and prevented any increase in the percentage of sclerosed glomeruli. This study compared the effects of prednisolone, azathioprine, warfarin, and dipyridamole (combination) with those of prednisolone alone in 80 children with newly diagnosed IgAN that showed diffuse mesangial proliferation. Patients were randomly assigned to receive either the combination or prednisolone alone for 2 yr. The primary end point was the disappearance of proteinuria, defined as urinary protein excretion <0.1 g/m2 per d, and the secondary end points were urinary protein excretion at the end of treatment, the change in the percentage of sclerosed glomeruli during the trial, and adverse effects. The two study groups were similar in terms of baseline characteristics. Thirty-nine of the 40 patients who received the combination and 39 of the 40 who received prednisolone completed the trial. Thirty-six (92.3%) of the 39 patients who received the combination and 29 (74.4%) of the 39 who received prednisolone reached the primary end point by the 2-yr follow-up point (P = 0.007 log-rank). The percentage of sclerosed glomeruli was unchanged in the patients who received the combination but increased from 3.1 +/- 4.8 to 14.6 +/- 15.2% in the prednisolone group (P = 0.0003). The frequency of adverse effects was similar in the two groups. It is concluded that combination treatment may be better for severe IgAN than treatment with prednisolone alone.

UR - http://www.scopus.com/inward/record.url?scp=33751404292&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33751404292&partnerID=8YFLogxK

U2 - 10.2215/CJN.01120905

DO - 10.2215/CJN.01120905

M3 - Article

C2 - 17699253

AN - SCOPUS:33751404292

VL - 1

SP - 511

EP - 517

JO - Clinical journal of the American Society of Nephrology : CJASN

JF - Clinical journal of the American Society of Nephrology : CJASN

SN - 1555-9041

IS - 3

ER -